Literature DB >> 30310479

The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

Sven M Francque1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease in western countries and is closely related to the metabolic syndrome. When NAFLD is associated with hepatocellular damage and inflammation (non-alcoholic steatohepatitis [NASH]) it can lead to severe liver disease. However, it has become clear that NAFLD is also associated with an increased risk of cardiovascular disease (CVD), independently of classical known risk factors for the latter. In the current review we briefly summarise the current clinical evidence on the role of NAFLD in CVD and discuss the potential mechanisms by which NAFLD can be linked to the pathophysiology of CVD.

Entities:  

Keywords:  cardiovascular events; non-alcoholic fatty liver disease; pathophysiology; steatosis

Year:  2014        PMID: 30310479      PMCID: PMC6159479          DOI: 10.15420/ecr.2014.9.1.10

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN: 1758-3756


  112 in total

1.  Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.

Authors:  Elena Lima-Cabello; María Victoria García-Mediavilla; María E Miquilena-Colina; Javier Vargas-Castrillón; Tamara Lozano-Rodríguez; Miguel Fernández-Bermejo; José Luis Olcoz; Javier González-Gallego; Carmelo García-Monzón; Sonia Sánchez-Campos
Journal:  Clin Sci (Lond)       Date:  2011-03       Impact factor: 6.124

2.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

3.  Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Giacomo Zoppini; Luciano Zenari; Giancarlo Falezza
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-12       Impact factor: 8.311

4.  Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders.

Authors:  Johannes B Ruige; Dominique P Ballaux; Tohru Funahashi; Ilse L Mertens; Yuji Matsuzawa; Luc F Van Gaal
Journal:  Am J Clin Nutr       Date:  2005-07       Impact factor: 7.045

5.  Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population.

Authors:  Maria Stepanova; Zobair M Younossi
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-13       Impact factor: 11.382

Review 6.  From the metabolic syndrome to NAFLD or vice versa?

Authors:  Ester Vanni; Elisabetta Bugianesi; Anna Kotronen; Samuele De Minicis; Hannele Yki-Järvinen; Gianluca Svegliati-Baroni
Journal:  Dig Liver Dis       Date:  2010-03-06       Impact factor: 4.088

7.  Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification.

Authors:  Dong-Hyuk Jung; Yong-Jae Lee; Hong-Yup Ahn; Jae-Yong Shim; Hye-Ree Lee
Journal:  Clin Chem Lab Med       Date:  2010-10-20       Impact factor: 3.694

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 10.  Inflammatory markers and cardiovascular risk in the metabolic syndrome.

Authors:  Christine Espinola-Klein; Tommaso Gori; Stefan Blankenberg; Thomas Munzel
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01
View more
  3 in total

1.  Integrative analysis of liver-specific non-coding regulatory SNPs associated with the risk of coronary artery disease.

Authors:  Ilakya Selvarajan; Anu Toropainen; Kristina M Garske; Maykel López Rodríguez; Arthur Ko; Zong Miao; Dorota Kaminska; Kadri Õunap; Tiit Örd; Aarthi Ravindran; Oscar H Liu; Pierre R Moreau; Ashik Jawahar Deen; Ville Männistö; Calvin Pan; Anna-Liisa Levonen; Aldons J Lusis; Sami Heikkinen; Casey E Romanoski; Jussi Pihlajamäki; Päivi Pajukanta; Minna U Kaikkonen
Journal:  Am J Hum Genet       Date:  2021-02-23       Impact factor: 11.025

2.  Effects of ω-3 PUFA-Rich Oil Supplementation on Cardiovascular Morphology and Aortic Vascular Reactivity of Adult Male Rats Submitted to an Hypercholesterolemic Diet.

Authors:  Mariely Mendes Furtado; Joana Érica Lima Rocha; Ana Victória da Silva Mendes; Renato Sampaio Mello Neto; Ana Karolinne da Silva Brito; José Otávio Carvalho Sena de Almeida; Emerson Iuri Rodrigues Queiroz; José Vinícius de Sousa França; Ana Lina de Carvalho Cunha Sales; Andreanne Gomes Vasconcelos; Wanessa Felix Cabral; Luana de Oliveira Lopes; Iolanda Souza do Carmo; Selma Aparecida Souza Kückelhaus; José Roberto de Souza de Almeida Leite; Adriana Maria Viana Nunes; Marcia Dos Santos Rizzo; Antônia Maria das Graças Lopes Citó; Ana Karina Marques Fortes Lustosa; Massimo Lucarini; Alessandra Durazzo; Maria do Carmo de Carvalho E Martins; Daniel Dias Rufino Arcanjo
Journal:  Biology (Basel)       Date:  2022-01-27

3.  The Beneficial Additive Effect of Silymarin in Metformin Therapy of Liver Steatosis in a Pre-Diabetic Model.

Authors:  Martina Hüttl; Irena Markova; Denisa Miklankova; Iveta Zapletalova; Martin Poruba; Zuzana Racova; Rostislav Vecera; Hana Malinska
Journal:  Pharmaceutics       Date:  2021-12-27       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.